What is a health benefit? An evaluation of EFSA opinions on health benefits with reference to probiotics

被引:34
作者
Binnendijk, K. H. [1 ]
Rijkers, G. T. [1 ]
机构
[1] Univ Coll Roosevelt, Dept Sci, NL-4331 CB Middelburg, Netherlands
关键词
beneficial to human health; European Food Safety Authority; health claim; microorganisms;
D O I
10.3920/BM2013.0019
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Probiotics are microorganisms that have a beneficial effect on the health of the host. However, before these effects can be referred to as beneficial to human health, such claims need to be evaluated by regulatory institutes such as the European Food Safety Authority (EFSA). The EFSA Panel on Dietetic Products, Nutrition and allergies (NDA) has published their opinions regarding health claims including probiotics, most of which were rejected in the past years. Using the EFSA database, the NDA dossiers published between 2005 and 2013 were analysed to provide an overview on what grounds certain health effects were accepted as beneficial and others not. The NDA Panel distinguishes between claims that are definitely beneficial, possibly beneficial or non-beneficial to human health. Overall, 78% of all analysed health claims are considered by the NDA Panel as (possibly) beneficial to human health, in particular the gut health effects. Since, in many cases, the scientific substantiation of a particular health claim was deemed insufficient, most applications were turned down. For future health claim applications concerning probiotics to be successful, they should include specific statements on what exactly the microorganism affects, and the scientific substantiation of the particular health claim should be based on the targeted (general) population.
引用
收藏
页码:223 / +
页数:40
相关论文
共 22 条
[1]   Guidance on the scientific requirements for health claims related to gut and immune function EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) [J].
Agostoni, Carlo ;
Bresson, Jean-Louis ;
Fairweather-Tait, Susan ;
Flynn, Albert ;
Golly, Ines ;
Korhonen, Hannu ;
Lagiou, Pagona ;
Lovik, Martinus ;
Marchelli, Rosangela ;
Martin, Ambroise ;
Moseley, Bevan ;
Neuhaeuser-Berthold, Monika ;
Przyrembel, Hildegard ;
Salminen, Seppo ;
Sanz, Yolanda ;
Strain, Sean ;
Strobel, Stephan ;
Tetens, Inge ;
Tome, Daniel ;
van Loveren, Hendrik ;
Verhagen, Hans .
EFSA JOURNAL, 2011, 9 (04)
[2]   Scientific Opinion on the substantiation of a health claim related to oat beta-glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006 [J].
Agostoni, Carlo ;
Bresson, Jean-Louis ;
Fairweather-Tait, Susan ;
Flynn, Albert ;
Golly, Ines ;
Korhonen, Hannu ;
Lagiou, Pagona ;
Lovik, Martinus ;
Marchelli, Rosangela ;
Martin, Ambroise ;
Moseley, Bevan ;
Neuhauser-Berthold, Monika ;
Przyrembel, Hildegard ;
Salminen, Seppo ;
Sanz, Yolanda ;
Strain, Sean ;
Strobel, Stephan ;
Tetens, Inge ;
Tome, Daniel ;
van Loveren, Hendrik ;
Verhagen, Hans .
EFSA JOURNAL, 2010, 8 (12)
[3]  
[Anonymous], 1946, Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, P19
[4]  
[Anonymous], 2013, EU REG NUTR HLTH CLA
[5]  
[Anonymous], 2001, Prevention
[6]  
EC, 2007, OFFICIAL J EUROPEA L, VL12, P3
[7]  
[EFSA EFSA (European Food Safety Authority)], 2008, EFSA J, V6
[8]  
EFSA (European Food Safety Authority), 2009, EFSA J, V7, P1177
[9]  
EFSA European Food Safety Authority. Panel on Dietetic Products Nutrition and Allergies (NDA), 2012, EFSA J, V10, P2858
[10]  
European Commission, 2010, OFFICIAL J EUROPEA L, VL37, P16